Severe cholestatic liver failure associated with gemcitabine adjuvant monotherapy for pancreatic cancer
Autor: | Shigeru Ottomo, Shinichi Egawa, Kuniharu Yamamoto, Fuyuhiko Motoi, Michiaki Unno, Yu Katayose, Naoaki Sakata, Takaho Okada, Toshiki Rikiyama |
---|---|
Rok vydání: | 2011 |
Předmět: |
medicine.medical_specialty
endocrine system diseases medicine.diagnostic_test business.industry medicine.medical_treatment Gastroenterology General Medicine Hepatology Jaundice medicine.disease Pancreaticoduodenectomy Gemcitabine Endocrinology Cholestasis Pancreatic cancer Internal medicine Edema medicine medicine.symptom business Liver function tests medicine.drug |
Zdroj: | Clinical Journal of Gastroenterology. 4:391-395 |
ISSN: | 1865-7265 1865-7257 |
DOI: | 10.1007/s12328-011-0257-2 |
Popis: | We report a case of severe hepatic failure caused by gemcitabine hydrochloride (GEM) monotherapy after pancreaticoduodenectomy for advanced pancreatic cancer. A 73-year-old woman received GEM as an adjuvant chemotherapy. She suffered from progressive edema, fatigue, and jaundice after the third GEM administration. Severe liver dysfunction and elevation of bilirubin was observed. A computed tomography scan and magnetic resonance imaging showed diffuse liver swelling suggesting severe hepatic edema with fat accumulation. Needle biopsy of the liver revealed remarkable cholestasis and fat deposition with mild damage of hepatocytes. Drug-induced liver failure was suspected. GEM-stimulated lymphocyte test was negative, but antinuclear antibody was elevated with a marked inflammatory response. She improved to an almost normal condition by steroid and liver protective therapies within a week. Although the frequency of liver failure induced by GEM monotherapy is very rare, it could be fatal. It is important to distinguish it from other causes of liver dysfunction following pancreaticoduodenectomy. Early detection and appropriate drug therapy can improve the prognosis. |
Databáze: | OpenAIRE |
Externí odkaz: |